Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...
Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback